$5.780
+0.102 (+1.76%)Zum Schluss
- High
- 5.890
- Open
- 5.690
- VWAP
- 5.79
- Vol
- 5.33K
- Mkt Cap
- 89.78M
- Low
- 5.690
- Amount
- 30.85K
- EV/EBITDA, TTM
- 0.00
InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets.
AI analysis of InterCure Ltd (INCR)
buyInterCure Ltd is a good buy right now due to its current price of 5.78, a significant 5-day change of +35.76%, and strong financial backing from a recent settlement of approximately $77 million. The main risk is its negative 1-year change of -29.08%, indicating past performance issues that investors should consider.
Analyst Ratings (12)
TD Cowen
$5
2023-04-12
TD Cowen
2023-04-12
Kursziel
$5
Barclays
—
2017-12-11
Barclays
2017-12-11
Kursziel
—
Credit Suisse
—
2017-11-14
Credit Suisse
2017-11-14
Kursziel
—
Keybanc
—
2017-11-13
Keybanc
2017-11-13
Kursziel
—
Baird
—
2017-11-10
Baird
2017-11-10
Kursziel
—
Bewertungskennzahlen
Event-Zeitleiste
News
8.508-24NASDAQ.COMInterCure Finalizes Settlement with Israeli Tax Authorities
8.508-19NewsfilterInterCure Implements Reverse Split to Maintain Nasdaq Listing
8.506-23NASDAQ.COMInterCure Secures NIS 22 Million Funding for Growth
8.506-22seekingalphaInterCure Signs Binding Term Sheet for Private Placement
- 8.506-15Newsfilter
InterCure Completes First Tranche of Botanico Acquisition Expanding U.S. Market Access
INCR FAQ — answered by Alphio AI
InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets. It operates in the Healthcare sector.
InterCure Ltd is a good buy right now due to its current price of 5.78, a significant 5-day change of +35.76%, and strong financial backing from a recent settlement of approximately $77 million. The main risk is its negative 1-year change of -29.08%, indicating past performance issues that investors should consider.
12 analysts cover INCR: 8 rate it Buy, 4 Hold and 0 Sell.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.